You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
新股配售 | 歐康維視生物-B一手中簽率5%,公開認購1895倍,國配76倍
uSMART友信智投 07-09 10:12

uSMART友信智投7月9日消息,歐康維視生物(01477)發佈《發售價及配發結果公告》。

【歐康維視生物-B的配售簡況】

1、發售價:14.66港元/股,為招股價(13.16-14.66港元)的上限

2、有效申購人數:356,899(甲組:341,214名,乙組:15,685名)

3、中簽率:1手中簽率5%,申購300手穩中1;甲組最多中2手,乙頭中2手,乙尾中12手

4、頂頭槌單:891張(每張穩中12手)

5、公開認購:1,895.76倍(甲組:932.85倍;乙組:2,858.66),乙組競爭更為激烈

6、回撥情況:國配的40%股份回撥給公開,最終公開的比例為50%,國配的比例為50%(假設超額配股權並無獲行使)

7、國際配售:超額認購約76(近期最高,遠超康基醫療的29倍),共154名承配人

8、基石投資者(14名):鎖定49.89%的發行股份(假設超額配股權並無獲行使)

9、關聯客戶(兩名):包銷商UBS AG香港分行的關聯客戶

10、超額配股權:國際發售中超額分配15,889,500股發售股份,有綠鞋

11、uSMART友信智投APP暗盤交易時段:7月9日16:15-18:30

【中簽率詳情】

甲組最多中2

乙組穩中2-12

甲組:

一手中簽率5%

申購300手穩中1手

乙組:

申購700手穩中2手

申購1400手穩中3手

申購4000手穩中6手

申購6000手穩中8手

申購8000手穩中10手

申購10593手穩中12手

以下為中簽分配基準:

圖片來源:披露易

【配售詳情】

香港公開發售

根據香港公開發售初步提呈發售的發售股份已獲大幅超額認購。合共接獲356,899份有效申請,認購合共20,081,747,000股香港發售股份,相當於根據香港公開發售初步可供認購的香港發售股份總數10,593,000股約1,895.76

由於香港公開發售的超額認購多於100倍,故已採取招股章程「全球發售的架構-全球發售-香港公開發售─重新分配」一節所披露的重新分配程式。香港公開發售項下的發售股份最終數目為52,965,000股發售股份,佔超額配股權獲行使前根據全球發售初步可供認購的發售股份總數的50%

國際發售

根據國際發售初步提呈發售的發售股份已獲大幅超額認購76,並已超額分配15,889,500股發售股份。國際發售項下共154名承配人。國際發售的發售股份最終數目為52,965,000股發售股份,佔超額配股權獲行使前根據全球發售初步可供認購發售股份總數的50%

基石投資者

基於發售價為每股發售股份14.66港元,基石投資者已合共認購52,853,500股發售股份,佔(a)緊隨全球發售完成後本公司已發行股本約9.19%,及(b)全球發售的發售股份數目49.89%,兩者均假設超額配股權未獲行使。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account